Polyrizon Ltd (PLRZ) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Polyrizon Announces Closing of $4.2 Million Initial Public Offering

Raanana, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in...

Form 424B4 - Prospectus [Rule 424(b)(4)]

Form 424B4 - Prospectus [Rule 424(b)(4)]

Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”

Raanana, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in...